Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 75%
filed 2026-06-08
Item 8.01
This disclosure concerns the issuance of $911 million in aggregate principal amount of asset-backed notes by a special-purpose trust, with filing required to satisfy undertakings for legality and tax opinions. While the issuance itself is material to investors in the notes, it does not fit cleanly into the standard taxonomy categories (not a traditional M&A activity, not a restatement, not an impairment). The 8-K is filed to document the closing of a securitization transaction and deliver required legal opinions, making this a material event that falls outside more specific categories.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-08
Item 7.01
The disclosure announces the redemption deadline for FGMC's public stockholders in connection with the business combination with BOXABL Inc. While the redemption deadline itself is a procedural milestone, it is material to investors as it represents a critical juncture in the SPAC merger process that affects shareholder rights and the capital structure of the combined entity. This does not fit neatly into the M&A activity category (which typically covers entry, completion, or termination of the transaction itself) but rather represents a material procedural event within an ongoing M&A transaction.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-08
Item 8.01
Liquidia Corporation announced its addition to the S&P SmallCap 600® Index effective June 22, 2026. Index inclusion is a material corporate event that typically increases visibility, liquidity, and institutional investor interest in the stock, affecting the total mix of information available to investors. While not fitting neatly into the standard taxonomy categories, this disclosure warrants classification as a material event.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-08
Item 1.01
FS KKR Capital Corp entered into a Sixteenth Supplemental Indenture on June 8, 2026 to issue $900 million in 7.500% notes due 2031, generating approximately $890 million in net proceeds. This represents a significant debt issuance and capital raise that materially increases the company's debt obligations.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-08
The filing discloses an amendment to extend IGC Pharma's Master Loan and Security Agreement with O-Bank Co., Ltd., increasing the facility fee from $48,000 to $60,000 while maintaining a $12,000,000 maximum aggregate limit. While Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of Direct Financial Obligation) are cited, this is a routine extension of an existing credit facility rather than a new material acquisition, debt covenant breach, or other specifically-defined event type. The modest fee increase and continuation of substantially unchanged terms suggest administrative renewal rather than a transformative financial event, though the extension of material debt facilities warrants disclosure as material to investors.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-08
Item 8.01
The Board formed a Transformation Committee on June 5, 2026, to oversee a company-wide transformation initiative focused on business positioning, cost structure optimization, growth opportunities, capital allocation, and portfolio composition. While the disclosure does not fit neatly into standard categories like M&A, executive appointment, or compensation, the formation of a board committee with explicit oversight of strategic transformation, cost optimization, and capital allocation decisions would likely affect a reasonable investor's assessment of the company's strategic direction and financial priorities. This is material governance activity related to significant business strategy changes, but lacks the specificity of other event types.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-06-08
Item 8.01
Cullinan Therapeutics announced initial Phase 1 clinical trial data for CLN-978 in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients from the OUTRACE trials, showing clinical activity with 71% of SLE patients achieving ≥4-point hSLEDAI reduction and 71% of RA patients demonstrating disease activity improvement, along with B cell depletion biomarker results. The data was presented at EULAR, a major rheumatology conference, and materially affects investor assessment of the company's pipeline development trajectory.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-06-08
Item 8.01
Tango Therapeutics disclosed initial safety and efficacy data from a Phase 1/2 combination trial of vopimetostat with RAS(ON) inhibitors, demonstrating strong efficacy signals (92% ORR in PDAC with daraxonrasib, 52% ORR with zoldonrasib) and favorable safety profiles. This clinical milestone data, which will advance the program to Phase 3 development, is material to investors' assessment of the company's pipeline and regulatory prospects.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-08
Item 8.01
Fair Isaac announced a new $2.0 billion stock repurchase program and entered into a $1.5 billion accelerated share repurchase (ASR) agreement with Wells Fargo Securities, with an upfront payment on June 8, 2026.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-08
Item 8.01
A material commercial customer is terminating two contracted projects effective June 16, 2026, reducing annual recurring revenue by $2.7 million (73% of that customer's $3.7 million prior ARR), though the company is pursuing mitigation measures and recertification opportunities.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-08
Item 7.01
Vor Biopharma announced that its partner RemeGen received conditional approval from China's NMPA for telitacicept in IgA nephropathy and full approval in Sjögren's disease. This represents a material regulatory milestone for a product in the company's pipeline, affecting investor assessment of the company's commercial prospects and partnership value. However, the event does not fit neatly into the standard taxonomy categories (not an earnings release, M&A activity, or executive change), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-08
Item 8.01
Mastercard completed a $5 billion debt offering across five tranches of notes with varying maturities and rates (2028–2036). While this is a material financing event affecting the company's capital structure and liquidity, it does not fit neatly into the standard 8-K taxonomy. The disclosure is routine debt issuance under an existing S-3 registration statement, not a covenant breach, going-concern issue, or other acute financial stress signal. Classified as other_material because the magnitude and nature of the transaction would affect a reasonable investor's assessment of the company's financial position, but the event itself is a standard capital markets transaction rather than a discrete material event type.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-08
Item 5.03
Stockholders approved an amendment to the certificate of incorporation to increase authorized common shares from 300 million to 600 million, doubling the company's equity issuance capacity.
View raw filing on EDGAR →
8-K
Other material
confidence 55%
filed 2026-06-08
Item 3.03
The filing discloses a material modification to rights of security holders, with substance incorporated by reference from Item 5.03, relating to the company's post-IPO capital structure and governance.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-08
Item 7.01
MSGE announced entry into a non-binding memorandum of understanding with Penn Station's Master Developer regarding potential transfer of the Infosys Theater at MSG and redevelopment coordination, contingent on execution of definitive agreements. While the MOU is non-binding and completion is uncertain, the disclosure involves a significant real estate transaction affecting MSG's operations and asset portfolio that would materially affect investor assessment of the company's strategic direction and asset base.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-08
Item 8.01
Shareholders approved a $4.20 per-share cash dividend to be paid from capital contribution reserves in four quarterly installments, with the first $1.05 installment payable on June 26, 2026. This material capital allocation decision was authorized at the annual meeting.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-08
Item 1.01
The filing discloses an amendment to a material revolving credit facility with City National Bank that extends the maturity date to June 8, 2029 (or March 31, 2029 if certain notes are not refinanced). While this is a material definitive agreement under Item 1.01, it does not fit cleanly into the M&A activity category—it is a debt facility amendment rather than an acquisition, disposition, merger, or change of control. The conditional maturity structure tied to refinancing of 8.50% notes due 2029 suggests potential refinancing risk, but the disclosure does not rise to the level of a covenant breach or going-concern warning. This is best classified as other_material because it is a material debt restructuring that affects the company's capital structure and liquidity profile, but lacks the specific hallmarks of the more defined event types.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-08
Item 7.01
Kraft Heinz is redeeming $1 billion of its $1.35 billion outstanding 3.875% Senior Notes due 2027, representing approximately 74% of the outstanding principal. While this is a debt management action rather than a traditional material event category, the scale of the redemption (reducing near-term debt maturity by a substantial amount) and the make-whole premium payment would materially affect the company's liquidity and financial position, warranting disclosure to investors.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-08
Item 8.01
A press release was issued on June 8, 2026 and furnished under Item 8.01 (Other Events). The specific substance of the announcement cannot be determined from the available classification data, as the actual content is referenced only as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-08
Item 8.01
CleanCore Solutions announced a comprehensive strategic pivot from a cleaning products and digital asset treasury company to an AI critical infrastructure company, including a non-binding letter of intent to acquire majority ownership in a data center project (the Midwest Project) and plans to explore selling its legacy cleaning products business and Dogecoin holdings to redeploy capital into data center and computing infrastructure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-08
Item 8.01
This disclosure describes the completion of a SPAC IPO and related private placements, including the exercise of an over-allotment option. While the IPO itself occurred on May 18, 2026 (prior to this 8-K filing), this Item 8.01 confirms the subsequent over-allotment exercise on May 20-21, 2026, and the resulting capital raised ($175.875 million in trust). This is a material capital-raising event for a blank-check company, but it does not fit neatly into the standard taxonomy categories (not an earnings release, M&A activity, or other specific event types). The disclosure is material to investors assessing the company's capitalization and ability to pursue a business combination.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-08
Item 5.03
Keystone adopted an Amended and Restated Memorandum and Articles of Association in connection with the IPO on June 2, 2026, reflecting governance document changes required for the newly public company.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-08
Item 3.03
The Board approved a bylaw amendment reducing the stockholder meeting quorum requirement from a majority (>50%) to 35% of voting power. While bylaw amendments are often routine, this particular change materially affects the governance rights and voting mechanics available to shareholders by lowering the threshold needed to conduct stockholder business. This modification could be material to investors assessing corporate governance and shareholder protections, though it does not fit neatly into the more specific event categories.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-08
Ribbon Acquisition Corp. disclosed under Item 8.01 that it deposited $125,000 into its trust account to extend the deadline for completing its initial business combination by one month (from May 15, 2026 to June 15, 2026). This extension is material to shareholders because it directly affects the timeline for the SPAC's merger or acquisition activity and the risk of liquidation if no business combination is consummated by the extended deadline. While this is a routine SPAC extension mechanism, the disclosure of a specific extension payment and revised deadline is material to investors' assessment of the company's status and timeline.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-08
Item 5.03
The Amended and Restated Memorandum and Articles of Association became effective and were filed with the Cayman Islands Registrar in connection with the IPO on June 4, 2026. The transition to public company governance documents is material to investors, though the disclosure is largely procedural with full terms referenced in the Registration Statement.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-08
Item 7.01
Neurogene announced completion of dosing in its EmboldenTM registrational trial for NGN-401 in Rett syndrome treatment. This is a material clinical development milestone for a gene therapy company, as completion of a Phase 3 registrational trial dosing is a significant de-risking event that affects investor assessment of the company's pipeline and regulatory pathway. However, it does not fit neatly into the standard taxonomy categories (not earnings, M&A, litigation, impairment, or other defined event types), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-08
Item 7.01
The filing discloses a press release providing an update on a "previously announced process to evaluate strategic alternatives" for the registrant. This language suggests ongoing M&A or restructuring activity, but the Item 7.01 disclosure is vague and does not specify the nature, status, or outcome of the strategic review. Without access to the attached press release (Exhibit 99.1), the precise event type cannot be determined; however, strategic alternatives processes typically involve potential M&A, divestitures, or going-concern considerations that would be material to investors. Classified as other_material pending review of the exhibit.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-08
The filing discloses entry into a material secured loan agreement (Item 1.01) with Agile Capital Funding, LLC on May 27, 2026, for approximately $260,000 borrowed with ~$389,740 total due over 32 weeks. While this creates a direct financial obligation (Item 2.03), it does not fit cleanly into the covenant_breach category (no breach alleged) or dilutive_issuance (debt, not equity). The subordinated nature and short repayment term suggest financial stress, but the event is best classified as a material financing arrangement outside the standard taxonomy.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-08
Tonix announced entry into an agreement with a group purchasing organization (GPO) providing coverage for TONMYA® to approximately 17 million U.S. commercially insured individuals, effective June 1, 2026. This represents a significant commercial milestone for the company's product, expanding market access beyond the ~75 million Medicaid beneficiaries already covered. While this is a material commercial development affecting the company's market opportunity and competitive position, it does not fit neatly into the standard 8-K event taxonomy (not M&A, not an executive change, not a financial restatement or impairment), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-08
Item 7.01
The Company disclosed that the DOE reinstated a Grant and extended the project and budget periods. This represents a material positive development for a battery technology company — reinstatement of federal funding and project extension would affect investor assessment of the company's financial resources and operational runway. However, the Item 7.01 disclosure is deliberately non-specific about the grant amount, original terms, or financial impact, and the actual press release content is not provided in the excerpt. Without those details, the event does not fit cleanly into earnings_release, ma_activity, or other more specific categories, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-08
Item 1.02
Celcuity completed a voluntary prepayment of approximately $137.5 million to fully satisfy and discharge its Amended and Restated Loan and Security Agreement with Oxford Finance and Innovatus Life Sciences, terminating all obligations under the facility and eliminating associated debt covenants.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-08
The filing discloses a 1-for-5 reverse stock split effectuated via Certificate of Change filed June 2, 2026, becoming effective June 11, 2026. While reverse stock splits are structural corporate actions, this one is material to investors as it reduces outstanding shares from ~365 million to ~73 million and affects trading mechanics, stock option/RSU adjustments, and fractional share treatment. The event does not fit neatly into the specific taxonomy categories (not a bylaw amendment alone, not M&A, not an impairment), making "other_material" the most appropriate classification for this significant capital structure modification.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-08
Item 5.03
The company changed its corporate name from Brilliant N.E.V. Corp. to Origin Tea Inc. and implemented a 1-for-8 reverse stock split, both approved by the Board and stockholders and filed with the Nevada Secretary of State on June 7, 2026. The reverse stock split proportionately reduces authorized shares from 345 million to 43.125 million and materially affects share count and trading mechanics.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-08
Item 8.01
The Board approved a material strategic pivot to the tea industry, including incorporation of foreign subsidiaries (Origin Tea Industry Limited in Hong Kong and a wholly foreign-owned enterprise in China), relocation of principal executive offices to Hainan, and authorization of a private placement financing program. The company remains a shell company with no securities yet issued under the financing program.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-08
Item 8.01
The disclosure concerns the conversion price of subordinated convertible notes due 2031, which affects the terms and potential dilution of an outstanding debt instrument. While the specific content is not provided, conversion price adjustments or resets on convertible securities are material to investors assessing capital structure and dilution risk, but do not fit neatly into the more specific event categories (not a new issuance under dilutive_issuance, not a covenant breach, and not exec/M&A activity). This is classified as other_material given its disclosure under Item 8.01 and relevance to the company's financial obligations.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-08
Item 8.01
Strive announced a bitcoin purchase of 32 BTC at ~$63,911 per coin during June 2-7, 2026, along with updates to its treasury holdings (cash, bitcoin, and STRC Stock positions) and share counts. While this reflects the company's ongoing bitcoin treasury strategy, the disclosure does not fit neatly into standard 8-K event categories. The purchase and treasury updates are material to investors assessing the company's asset composition and capital allocation, but the event is primarily an operational/treasury update rather than a discrete corporate action (M&A, impairment, covenant breach, etc.). Classified as other_material because it is a material treasury/asset activity that does not align with more specific event types.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-08
Item 8.01
The disclosure announces a monthly common dividend of $0.08 per share declared by the Board of Trustees, payable July 31, 2026. While dividend declarations are routine for REITs and BDCs like Ellington Credit, this is material to investors as it affects shareholder returns and capital allocation. However, it does not fit neatly into the more specific event categories (not earnings, not executive action, not M&A, etc.), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-08
Item 7.01
This Item 7.01 disclosure is a business update providing portfolio performance metrics, capital inflows, and liquidity position for TPG Twin Brook Capital Income Fund. While it includes material operational information (9.8% annualized returns since inception, $4.5 billion portfolio, $181 million capital inflows, $832 million liquidity), it does not fit neatly into the specific event categories. The disclosure is a periodic business update rather than a discrete material event like M&A, executive changes, restatement, or covenant breach. It is material to investors assessing fund performance and financial health, but lacks the triggering event character of the more specific categories.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-08
Item 8.01
The Board authorized a share repurchase program for up to 1,000,000 shares funded by subsidiary dividends, with authority to enter Rule 10b5-1 trading plans. While share repurchases are capital allocation decisions material to investors, this disclosure does not fit the more specific event categories (not an earnings release, executive change, M&A, impairment, or covenant breach). The authorization itself—distinct from actual repurchases—is a material corporate action affecting shareholder value and capital structure.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-08
Item 1.01
This disclosure describes a material definitive agreement for share repurchase from a related party (Magnus Holdings Co., Ltd.) for up to $52.5 million under the Company's existing $1.25 billion repurchase authorization. While share repurchases are routine capital allocation activities, this transaction involves a related-party component and structured pricing mechanics that distinguish it from standard open-market buybacks. The agreement does not constitute a traditional M&A activity, dilutive issuance, or other enumerated event type, making "other_material" the most appropriate classification for this related-party share purchase arrangement.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-08
Item 8.01
The Board authorized a stock repurchase program for up to $100 million over 36 months, effective June 3, 2026, replacing the prior 2023 program. This capital allocation decision is material to investors but does not fit the more specific event taxonomy.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-08
Item 8.01
This disclosure reports the completion of FortuneX's IPO on May 26, 2026 (7.5M units at $10/unit for $75M gross proceeds), the full exercise of the underwriters' over-allotment option on May 29, 2026 (1.125M additional units for $11.25M), and a concurrent private placement to the Sponsor (15,000 units for $150K). While the IPO itself is a capital-raising event material to investors, the Item 8.01 framing and the absence of a formal earnings release or press release exhibit suggest this is a post-closing confirmation rather than an earnings_release. The event is material (total gross proceeds ~$86.4M) but does not fit neatly into the more specific categories; it is best classified as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-08
Item 7.01
Vivakor announced entry into a significant recurring crude oil transaction covering 100,000 barrels per month, representing approximately $108 million in annualized revenue. This material commercial arrangement affects investor assessment of the company's revenue prospects and business operations.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-05
Item 7.01
Haemonetics announced a material restructuring of its reportable segment structure, combining Plasma and Blood Center into a single "Apheresis" segment and renaming Hospital to "MedSurg," effective Q1 FY2027. This change affects how investors will receive and analyze financial information going forward, including recast historical data and guidance. While segment reorganizations are administrative in nature, this disclosure materially impacts the transparency and comparability of financial reporting, making it material to investors' assessment of the company's business performance and structure.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-05
Item 7.01
Hallador Energy announced that its subsidiary was selected by the U.S. Department of Energy to begin award negotiations for up to $27.2 million in federal funding to modernize the Merom Generating Station. This represents a material development—a significant potential capital infusion and government recognition—but does not fit neatly into the standard taxonomy categories (not M&A, not an executive change, not a restatement or impairment). The funding is conditional ("potential" and "award negotiations"), making it distinct from a completed transaction, but the scale and strategic importance to a coal-focused energy company warrant material classification.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-05
Item 8.01
Hut 8 Corp. announced the pricing of a $4.25 billion senior secured debt offering by its subsidiary Beacon Point DC LLC. While this is a material financing event that would affect investor assessment of the company's capital structure and liquidity, it does not fit cleanly into the standard taxonomy categories (not an earnings release, M&A activity, impairment, or other specifically enumerated event types). The disclosure is material because a $4.25 billion debt issuance significantly impacts the registrant's financial position and obligations.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-05
Item 8.01
Duke Energy Carolinas consummated the issuance and sale of $2.4 billion in mortgage bonds across three series (4.65% due 2031, 5.15% due 2036, and 5.75% due 2056) on June 5, 2026. While this is a material debt financing event affecting the company's capital structure and financial position, it does not fit cleanly into the standard 8-K taxonomy categories. The disclosure is a straightforward debt issuance completion rather than a restatement, impairment, covenant breach, or other more specific event type, warranting classification as "other_material."
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-05
Item 8.01
The Company is winding down two material agreements (Native Markets Temporary Use Agreement and Felix Foundation HAUS Agreement) involving approximately $28.7 million in combined asset value as of March 31, 2026. While this involves repositioning of assets rather than a traditional M&A transaction, covenant breach, or other specifically-defined event type, the termination of these material agreements and the return of ~800,000 HYPE tokens represents a significant strategic shift that would affect a reasonable investor's assessment of the Company's operations and asset positioning.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-05
Item 3.03
The filing discloses a material modification to the rights of security holders, specifically relating to preferred stock rights, in connection with the transactions described in the 8-K.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-05
Item 3.03
GPGI completed a reincorporation from Delaware to Nevada on June 5, 2026, materially modifying stockholder rights by changing the governing law and corporate charter. The reincorporation represents a significant corporate governance restructuring that affects the legal framework governing shareholder rights.
View raw filing on EDGAR →